Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present OncoSec Medical Incorporated (OTC: ONCS).

Full DD Report for ONCS

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.7950.78510.79550.74527,611
2018-12-130.820.79490.85870.78911,236,221
2018-12-120.840.8140.850.8111,231,890
2018-12-110.890.8210.890.783,383,029
2018-12-100.900.87521.130.8317,545,519

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on ONCS.


About OncoSec Medical Incorporated (OTC: ONCS)

Logo for OncoSec Medical Incorporated (OTC: ONCS)

OncoSec Medical Incorporated is a biopharmaceutical company developing its proprietary DNA based intratumoral cancer immunotherapy technology, ImmunoPulse. OncoSec Medical s core technology is designed to enhance the local delivery and uptake of DNA IL and other DNA based agents that target tumor induced immune subversion pathways. ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well tolerated and preliminary evidence of anti tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments. OncoSec Medical s lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma. A Phase b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti PD pembrolizumab , for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers. The company is also focused on identifying and developing new DNA encoded proteins that target key pathways of tumor induced immune subversion, investigating additional tumor indications, and evaluating other combination based immunotherapy approaches. For more information, please visit www.oncosec.com.

 

 

 

Current Management

  • Punit Dhillon / President, CEO
    • Formerly the VP of finance and operations at Inovio Pharmaceuticals, Inc., Mr. Dhillon raised over million through multiple financings and several licensing deals. He was also instrumental to the successful inlicensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and the merger with VGX Pharmaceuticals. Mr. Dhillon has also been a consultant and board member for several early stage life science companies.
  • Richard Slansky / CFO
  • Mai Hope Le / Chief Med. Officer
    • Dr. Mai H. Le has a strong background in drug development, with extensive experience in clinical research and regulatory affairs. Prior to joining OncoSec, Dr. Le was medical director at Calithera Biosciences, Inc., where she formulated and launched the early clinical development plans for a novel small molecule inhibitor of glutaminase for a variety of solid and hematological tumor indications. From to , she was associate medical director and medical director at Proteolix, Inc., Onyx Pharmaceuticals, Inc. and Plexxikon Inc. Her work at Proteolix and, later, Onyx Pharmaceuticals, was critical to the accelerated approval of carfilzomib Kyprolis , a secondgeneration proteasome inhibitor for the treatment of relapsed/refractory multiple myeloma. Prior to entering medical school, Dr. Le managed clinical trials for PAREXEL International Corporation in Waltham, Massachusetts. Dr. Le received her medical degree at the University of Rochester School of Medicine and Dentistry and completed her residency in Clinical Pathology/Laboratory Medicine at the University of California at San Francisco. She received her bachelor of arts in biology from Cornell University.
  • Robert Pierce / Chief Scientific Officer
    • Dr. Robert H. Pierce joins OncoSec from Merck Research Labs where he was the Executive Director/Member of the Global AntiPD Development Team. Dr. Pierce is well regarded for his careerlong research into mechanisms of immune tolerance. He is the coauthor of over fifty peerreviewed journal articles and book chapters. Dr. Pierce received his postdoctoral training at the University of Washington, Seattle, WA, his graduate education and training at Brown University School of Medicine in Providence, RI, and received his undergraduate education at Yale University in New Haven, CT. As a Fulbright Award recipient, Dr. Pierce studied Philosophy at the AlbertLudwigsUniversity in Freiburg, Germany.
  • Sheela MohanPeterson / General Counsel
    • Sheela MohanPeterson has spent more than years working in the pharmaceutical and biotech industries, most recently as a Senior Patent Counsel with Merck amp Co., Inc. She received her bachelor s degree in biology from Washington University in St. Louis, and her master s degree in molecular biology from Rutgers University. Ms. MohanPeterson began her career in as a scientist in the Tumor Biology department of ScheringPlough Research Institute in Bloomfield, New Jersey. In , she transferred to the Human Immunology department at DNAX Research Institute, a subsidiary of ScheringPlough, located in Palo Alto, California. After graduating from law school in , she began her career as a patent attorney at Incyte Genomics in Palo Alto, and then as a patent counsel at Roche Bioscience, also in Palo Alto. In , she returned to DNAX as a senior patent counsel and remained there for several years after a merger with Merck.
  • Andrew Cronauer / Lawyer
  • Jordyn Kopin / Corp. Commun.
  • Avtar Dhillon / Chairman
    • As former president and CEO of Inovio Pharmaceuticals, Inc. formerly Inovio Biomedical Corporation , Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over million and secured more than million in licensing deals from global companies including Merck and Wyeth now Pfizer . Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.
  • James Demesa / Director
    • Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and preclinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company. Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a cofounder of CommGeniX and MedXcel.
  • Punit Dhillon / Director
    • Formerly the VP of finance and operations at Inovio Pharmaceuticals, Inc., Mr. Dhillon raised over million through multiple financings and several licensing deals. He was also instrumental to the successful inlicensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and the merger with VGX Pharmaceuticals. Mr. Dhillon has also been a consultant and board member for several early stage life science companies.
  • Anthony Maida, III / Director
    • Most recently, Dr. Maida was vice president of clinical research and general manager of oncology, worldwide, for a leading international contract research organization. He has served as president and CEO of both Replicon NeuroTherapeutics, Inc. and Jenner Therapies, interim CEO for Trellis Bioscience, Inc., and president of CancerVax Corporation, where he secured the Company s first financing of million. Today, Dr. Maida serves as a senior advisor for multiple investment firms and life science companies. He also sits on the board of directors of Spectrum Pharmaceuticals, Inc.

Current Share Structure

  • Market Cap: $89,064,216 - 03/21/2018
  • Issue and Outstanding: 51,482,206 - 03/07/2018

 


Recent Filings from (OTC: ONCS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: April, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 09 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 02 2018

 

 


Daily Technical Chart for (OTC: ONCS)

Daily Technical Chart for (OTC: ONCS)


Stay tuned for daily updates and more on (OTC: ONCS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ONCS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ONCS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ONCS and does not buy, sell, or trade any shares of ONCS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/